Cytomegalovirus replication kinetics in solid organ transplant recipients managed by preemptive therapy

American Journal of Transplantation

Volumn 12, Issue 9, 2012, Pages 2457-2464

  Atabani, S F ^a   Smith, C ^a   Atkinson, C ^a   Aldridge, R W ^a   Rodriguez Peralvarez M ^a   Rolando, N ^a   Harber, M ^a   Jones, G ^a   O'Riordan, A ^a   Burroughs, A K ^a   Thorburn, D ^a   O'Beirne, J ^a   Milne, R S B ^a   Emery, V C ^a   Griffiths, P D ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Allograft; cytomegalovirus replication; liver; preemptive management; renal

Indexed keywords

GANCICLOVIR; METHYLPREDNISOLONE; VALGANCICLOVIR; VIRUS DNA;

ACUTE GRAFT REJECTION; ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; BLOOD SAMPLING; CYTOMEGALOVIRUS INFECTION; DISEASE DURATION; FEMALE; GRAFT RECIPIENT; HUMAN; INFECTION PREVENTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIMARY INFECTION; PRIORITY JOURNAL; REINFECTION; TREATMENT DURATION; VIREMIA; VIRUS LOAD; VIRUS REACTIVATION; VIRUS REPLICATION;

BIOLOGICAL MARKERS; CYTOMEGALOVIRUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION; POLYMERASE CHAIN REACTION; VIRAL LOAD; VIRUS REPLICATION;

EID: 84865584215     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2012.04087.x     Document Type: Article

References (25)

1. Fishman JA, Rubin RH,. Infection in organ-transplant recipients. N Engl J Med 1998; 338: 1741-1751. (Pubitemid 28268592)
2. Emery VC, Sabin CA, Cope AV, Gor D, Hassan-Walker AF, Griffiths PD,. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000; 355: 2032-2036. (Pubitemid 30339241)
3. Regoes RR, Bowen EF, Cope AV, et al,. Modelling cytomegalovirus replication patterns in the human host: Factors important for pathogenesis. Proc Biol Sci 2006; 273: 1961-1967. (Pubitemid 46939935)
4. Humar A, Lebranchu Y, Vincenti F, et al,. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010; 10: 1228-1237.
5. Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M,. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000; 356: 645-649. (Pubitemid 30627592)
6. Atkinson C, Emery VC,. Cytomegalovirus quantification: Where to next in optimising patient management? J Clin Virol 2011; 51: 223-228.
7. Jung C, Engelmann E, Borner K, Offermann G,. Preemptive oral ganciclovir therapy versus prophylaxis to prevent symptomatic cytomegalovirus infection after kidney transplantation. Transplant Proc 2001; 33: 3621-3623. (Pubitemid 34042704)
8. Khoury JA, Storch GA, Bohl DL, et al,. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006; 6: 2134-2143. (Pubitemid 44199547)
9. Reischig T, Nemcova J, Vanecek T, et al,. Intragraft cytomegalovirus infection: A randomized trial of valacyclovir prophylaxis versus pre-emptive therapy in renal transplant recipients. Antivir Ther 2010; 15: 23-30.
10. Griffiths PD, Stanton A, McCarrell E, et al,. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: A phase 2 randomised placebo-controlled trial. Lancet 2011 Apr 9; 377: 1256-1263.
11. Mattes FM, Hainsworth EG, Hassan-Walker AF, et al,. Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valganciclovir. J Infect Dis 2005; 191: 89-92. (Pubitemid 40041405)
12. Cope AV, Sabin C, Burroughs A, Rolles K, Griffiths PD, Emery VC,. Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation. J Infect Dis 1997; 176: 1484-1490. (Pubitemid 27518147)
13. Emery VC, Cope AV, Bowen EF, Gor D, Griffiths PD,. The dynamics of human cytomegalovirus replication in vivo. J Exp Med 1999; 190: 177-182. (Pubitemid 29354911)
14. Emery VC, Hassan-Walker AF, Burroughs AK, Griffiths PD,. Human cytomegalovirus (HCMV) replication dynamics in HCMV-naive and -experienced immunocompromised hosts. J Infect Dis 2002; 185: 1723-1728. (Pubitemid 34615465)
15. Whalley SA, Brown D, Webster GJ, et al,. Evolution of hepatitis B virus during primary infection in humans: transient generation of cytotoxic T-cell mutants. Gastroenterology 2004; 127: 1131-1138. (Pubitemid 39345882)
16. Kotton CN, Kumar D, Caliendo AM, et al,. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89: 779-795.
17. Ljungman P, Griffiths P, Paya C,. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094-1097. (Pubitemid 34289682)
18. Cope AV, Sweny P, Sabin C, Rees L, Griffiths PD, Emery VC,. Quantity of cytomegalovirus viruria is a major risk factor for cytomegalovirus disease after renal transplantation. J Med Virol 1997; 52: 200-205. (Pubitemid 27239321)
19. Humar A, Kumar D, Boivin G, Caliendo AM,. Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. J Infect Dis 2002; 186: 829-833. (Pubitemid 35013436)
20. Preiksaitis JK, Sandhu J, Strautman M,. The risk of transfusion-acquired CMV infection in seronegative solid-organ transplant recipients receiving non-WBC-reduced blood components not screened for CMV antibody (1984 to 1996): Experience at a single Canadian center. Transfusion 2002; 42: 396-402.
21. Mattes FM, Vargas A, Kopycinski J, et al,. Functional impairment of cytomegalovirus specific CD8 T cells predicts high-level replication after renal transplantation. Am J Transplant 2008; 8: 990-999. (Pubitemid 351537766)
22. La RC, Krishnan A, Longmate J, et al,. Programmed death-1 expression in liver transplant recipients as a prognostic indicator of cytomegalovirus disease. J Infect Dis 2008; 197: 25-33. (Pubitemid 351263462)
23. Nebbia G, Mattes FM, Smith C, et al,. Polyfunctional cytomegalovirus- specific CD4+ and pp65 CD8+ T cells protect against high-level replication after liver transplantation. Am J Transplant 2008; 8: 2590-2599.
24. Sester M, Sester U, Gartner B, et al,. Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation. Transplantation 2001; 71: 1287-1294. (Pubitemid 32507149)
25. Sester U, Gartner BC, Wilkens H, et al,. Differences in CMV-specific T-cell levels and long-term susceptibility to CMV infection after kidney, heart and lung transplantation. Am J Transplant 2005; 5: 1483-1489. (Pubitemid 40839442)